AMGN
Price
$310.09
Change
+$4.39 (+1.44%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
151.69B
19 days until earnings call
BIIB
Price
$130.71
Change
-$0.61 (-0.46%)
Updated
Apr 3 closing price
Capitalization
31.34B
27 days until earnings call
Ad is loading...

AMGN vs BIIB

Header iconAMGN vs BIIB Comparison
Open Charts AMGN vs BIIBBanner chart's image
Amgen
Price$310.09
Change+$4.39 (+1.44%)
Volume$78.28K
Capitalization151.69B
Biogen
Price$130.71
Change-$0.61 (-0.46%)
Volume$1.76M
Capitalization31.34B
AMGN vs BIIB Comparison Chart
Loading...
AMGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMGN vs. BIIB commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Hold and BIIB is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (AMGN: $309.85 vs. BIIB: $130.71)
Brand notoriety: AMGN and BIIB are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AMGN: 108% vs. BIIB: 104%
Market capitalization -- AMGN: $151.69B vs. BIIB: $31.34B
AMGN [@Pharmaceuticals: Major] is valued at $151.69B. BIIB’s [@Pharmaceuticals: Major] market capitalization is $31.34B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMGN’s FA Score shows that 4 FA rating(s) are green whileBIIB’s FA Score has 0 green FA rating(s).

  • AMGN’s FA Score: 4 green, 1 red.
  • BIIB’s FA Score: 0 green, 5 red.
According to our system of comparison, AMGN is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMGN’s TA Score shows that 3 TA indicator(s) are bullish while BIIB’s TA Score has 5 bullish TA indicator(s).

  • AMGN’s TA Score: 3 bullish, 4 bearish.
  • BIIB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both AMGN and BIIB are a bad buy in the short-term.

Price Growth

AMGN (@Pharmaceuticals: Major) experienced а +1.33% price change this week, while BIIB (@Pharmaceuticals: Major) price change was -6.86% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.77%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was -8.16%.

Reported Earning Dates

AMGN is expected to report earnings on Apr 23, 2025.

BIIB is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.77% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMGN($152B) has a higher market cap than BIIB($31.3B). BIIB has higher P/E ratio than AMGN: BIIB (26.95) vs AMGN (22.66). AMGN YTD gains are higher at: 18.847 vs. BIIB (-14.524). AMGN has higher annual earnings (EBITDA): 14.8B vs. BIIB (2.04B). AMGN has more cash in the bank: 10.9B vs. BIIB (1.05B). BIIB has less debt than AMGN: BIIB (7.34B) vs AMGN (64.6B). AMGN has higher revenues than BIIB: AMGN (28.2B) vs BIIB (9.84B).
AMGNBIIBAMGN / BIIB
Capitalization152B31.3B486%
EBITDA14.8B2.04B726%
Gain YTD18.847-14.524-130%
P/E Ratio22.6626.9584%
Revenue28.2B9.84B287%
Total Cash10.9B1.05B1,038%
Total Debt64.6B7.34B880%
FUNDAMENTALS RATINGS
AMGN vs BIIB: Fundamental Ratings
AMGN
BIIB
OUTLOOK RATING
1..100
8457
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
94
Overvalued
PROFIT vs RISK RATING
1..100
18100
SMR RATING
1..100
1667
PRICE GROWTH RATING
1..100
4664
P/E GROWTH RATING
1..100
996
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AMGN's Valuation (23) in the Biotechnology industry is significantly better than the same rating for BIIB (94). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.

AMGN's Profit vs Risk Rating (18) in the Biotechnology industry is significantly better than the same rating for BIIB (100). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.

AMGN's SMR Rating (16) in the Biotechnology industry is somewhat better than the same rating for BIIB (67). This means that AMGN’s stock grew somewhat faster than BIIB’s over the last 12 months.

AMGN's Price Growth Rating (46) in the Biotechnology industry is in the same range as BIIB (64). This means that AMGN’s stock grew similarly to BIIB’s over the last 12 months.

AMGN's P/E Growth Rating (9) in the Biotechnology industry is significantly better than the same rating for BIIB (96). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMGNBIIB
RSI
ODDS (%)
Bearish Trend 2 days ago
56%
Bullish Trend 1 day ago
69%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 1 day ago
50%
Momentum
ODDS (%)
Bearish Trend 2 days ago
51%
Bearish Trend 1 day ago
68%
MACD
ODDS (%)
Bearish Trend 2 days ago
44%
Bearish Trend 1 day ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
54%
Bearish Trend 1 day ago
70%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
47%
Bearish Trend 1 day ago
70%
Advances
ODDS (%)
Bullish Trend 4 days ago
57%
Bullish Trend 25 days ago
53%
Declines
ODDS (%)
Bearish Trend 2 days ago
51%
Bearish Trend 1 day ago
69%
BollingerBands
ODDS (%)
N/A
Bullish Trend 1 day ago
69%
Aroon
ODDS (%)
Bullish Trend 2 days ago
48%
Bullish Trend 1 day ago
34%
View a ticker or compare two or three
Ad is loading...
AMGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FWRG18.420.51
+2.85%
First Watch Restaurant Group
FUL58.040.86
+1.50%
HB Fuller Company
GPN99.601.16
+1.18%
Global Payments
UTMD55.78-0.22
-0.39%
Utah Medical Products
BTOG0.18-0.02
-10.11%
Bit Origin Limited

AMGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with PFE. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMGN
1D Price
Change %
AMGN100%
-0.40%
PFE - AMGN
43%
Loosely correlated
+0.65%
GSK - AMGN
38%
Loosely correlated
-0.61%
NVS - AMGN
35%
Loosely correlated
+1.06%
ABBV - AMGN
35%
Loosely correlated
-0.52%
BIIB - AMGN
33%
Loosely correlated
-0.54%
More